I-Mab Biopharma - Company Profile

BioCentury | Apr 15, 2021

Deals

Genechem’s bispecifics deal with I-Mab marks debut for a global strategy 20 years in the making

...past five years.Shanghai Genechem Co. Ltd. and I-Mab Biopharma (NASDAQ:IMAB...
...– Tumor antigen MG7 BC Staff Shanghai Genechem Co. Ltd. I-Mab Biopharma...

BioCentury | Apr 13, 2021

Regulation

Competence & continuity at CDER; plus BIO 3.0, AACR and 2Q preview: a BioCentury podcast

...Cranmer discuss what last week’s deal with I-Mab Biopharma (NASDAQ:IMAB...

BioCentury | Mar 10, 2021

Deals

I-Mab signs first two deals of immuno-oncology discovery initiative

...the start of a new discovery initiative to build out the Chinese biotech’s immuno-oncology pipeline. I-Mab Biopharma (NASDAQ:IMAB...
...in addition to an internal preclinical bispecific platform that’s focused on immunotherapy targets for cancer. Stephen Hansen I-Mab Biopharma Complix...

BioCentury | Feb 26, 2021

Distillery Therapeutics

Antibody-drug conjugate targeting CLDN6 for liver cancer

DISEASE CATEGORY: Cancer INDICATION: Liver cancer An antibody-drug conjugate targeting the tight junction protein CLDN6 could treat hepatocellular carcinoma (HCC). In patients, high tumor levels of CLDN6 protein were associated with poor overall and disease-free...

BioCentury | Jan 16, 2021

Product Development

Arcus’ CD73 inhibitor challenges AZ’s oleclumab, at least six others follow in oncology: Data Byte

...these groups, two also have their compounds in Phase I testing for COVID-19. Selina Koch [MERGED] AstraZeneca plc I-Mab Biopharma Surface...

BioCentury | Jan 4, 2021

Finance

With first royalty deal done, CBC’s R-Bridge fund aims for Asia-focused biotechs’ non-dilutive sweet spots

...CBC has been a key investor in cross-border licensing company Everest Medicines Ltd. (HKEX:1952); I-Mab Biopharma (NASDAQ:IMAB...

BioCentury | Dec 8, 2020

Politics, Policy & Law

Data Byte: NASDAQ’s Chinese biotechs may look to Hong Kong for secondary listings as House passes auditing bill

...point,” Lin added. At the 7th China Healthcare Summit hosted by BioCentury-BayHelix last month, I-Mab Biopharma (NASDAQ:IMAB...

BioCentury | Nov 18, 2020

Product Development

Annual BayHelix awards highlight China’s growing life sciences sector; HKEX’s Li, Zai’s Du, Innovent among winners

...conducting a Phase II U.S. trial of the mAb, to which it has ex-China rights.I-Mab Biopharma (NASDAQ:IMAB...
...Optical won the award in the corporate category.TARGETSPD-1 (PDCD1; CD279) – Programmed cell death 1 Hongjiang Li I-Mab Biopharma Jiangsu...

BioCentury | Nov 14, 2020

Product Development

ASH 2020 snapshot: efficacy data in hot emerging areas

...Inc. (NASDAQ:ALXO), Gilead Sciences Inc. (NASDAQ:GILD), I-Mab Biopharma (NASDAQ:IMAB...
...alpha constant Karen Tkach Tuzman Gilead Sciences Inc. Forty Seven Inc. I-Mab Biopharma Trillium...

BioCentury | Nov 14, 2020

Deals

Innovation in a hurry: China biotechs see a fast track to global stage – survey

...& Co., who cited recent out-licensing deals by I-Mab Biopharma (NASDAQ:IMAB...
...MediTech Ltd. Sofinnova Partners Hua Medicine Ltd. CStone Pharmaceuticals Co. Ltd. I-Mab Biopharma Qiming...

Items per page:

1 - 10 of 95

BioCentury | Apr 15, 2021

Deals

Genechem’s bispecifics deal with I-Mab marks debut for a global strategy 20 years in the making

...past five years.Shanghai Genechem Co. Ltd. and I-Mab Biopharma (NASDAQ:IMAB...
...– Tumor antigen MG7 BC Staff Shanghai Genechem Co. Ltd. I-Mab Biopharma...

BioCentury | Apr 13, 2021

Regulation

Competence & continuity at CDER; plus BIO 3.0, AACR and 2Q preview: a BioCentury podcast

...Cranmer discuss what last week’s deal with I-Mab Biopharma (NASDAQ:IMAB...

BioCentury | Mar 10, 2021

Deals

I-Mab signs first two deals of immuno-oncology discovery initiative

BioCentury | Feb 26, 2021

Distillery Therapeutics

Antibody-drug conjugate targeting CLDN6 for liver cancer

BioCentury | Jan 16, 2021

Product Development

Arcus’ CD73 inhibitor challenges AZ’s oleclumab, at least six others follow in oncology: Data Byte

...these groups, two also have their compounds in Phase I testing for COVID-19. Selina Koch [MERGED] AstraZeneca plc I-Mab Biopharma Surface...

BioCentury | Jan 4, 2021

Finance

With first royalty deal done, CBC’s R-Bridge fund aims for Asia-focused biotechs’ non-dilutive sweet spots

...CBC has been a key investor in cross-border licensing company Everest Medicines Ltd. (HKEX:1952); I-Mab Biopharma (NASDAQ:IMAB...

BioCentury | Dec 8, 2020

Politics, Policy & Law

Data Byte: NASDAQ’s Chinese biotechs may look to Hong Kong for secondary listings as House passes auditing bill

...point,” Lin added. At the 7th China Healthcare Summit hosted by BioCentury-BayHelix last month, I-Mab Biopharma (NASDAQ:IMAB...

BioCentury | Nov 18, 2020

Product Development

Annual BayHelix awards highlight China’s growing life sciences sector; HKEX’s Li, Zai’s Du, Innovent among winners

BioCentury | Nov 14, 2020

Product Development

ASH 2020 snapshot: efficacy data in hot emerging areas

...Inc. (NASDAQ:ALXO), Gilead Sciences Inc. (NASDAQ:GILD), I-Mab Biopharma (NASDAQ:IMAB...
...alpha constant Karen Tkach Tuzman Gilead Sciences Inc. Forty Seven Inc. I-Mab Biopharma Trillium...

BioCentury | Nov 14, 2020

Deals

Innovation in a hurry: China biotechs see a fast track to global stage – survey

...& Co., who cited recent out-licensing deals by I-Mab Biopharma (NASDAQ:IMAB...
...MediTech Ltd. Sofinnova Partners Hua Medicine Ltd. CStone Pharmaceuticals Co. Ltd. I-Mab Biopharma Qiming...

Items per page:

1 - 10 of 95

Genechem’s bispecifics deal with I-Mab marks debut for a global strategy 20 years in the making

Competence & continuity at CDER; plus BIO 3.0, AACR and 2Q preview: a BioCentury podcast

I-Mab signs first two deals of immuno-oncology discovery initiative

Antibody-drug conjugate targeting CLDN6 for liver cancer

Arcus’ CD73 inhibitor challenges AZ’s oleclumab, at least six others follow in oncology: Data Byte

With first royalty deal done, CBC’s R-Bridge fund aims for Asia-focused biotechs’ non-dilutive sweet spots

Data Byte: NASDAQ’s Chinese biotechs may look to Hong Kong for secondary listings as House passes auditing bill

Annual BayHelix awards highlight China’s growing life sciences sector; HKEX’s Li, Zai’s Du, Innovent among winners

ASH 2020 snapshot: efficacy data in hot emerging areas

Innovation in a hurry: China biotechs see a fast track to global stage – survey

Genechem’s bispecifics deal with I-Mab marks debut for a global strategy 20 years in the making

Competence & continuity at CDER; plus BIO 3.0, AACR and 2Q preview: a BioCentury podcast

I-Mab signs first two deals of immuno-oncology discovery initiative

Antibody-drug conjugate targeting CLDN6 for liver cancer

Arcus’ CD73 inhibitor challenges AZ’s oleclumab, at least six others follow in oncology: Data Byte

With first royalty deal done, CBC’s R-Bridge fund aims for Asia-focused biotechs’ non-dilutive sweet spots

Data Byte: NASDAQ’s Chinese biotechs may look to Hong Kong for secondary listings as House passes auditing bill

Annual BayHelix awards highlight China’s growing life sciences sector; HKEX’s Li, Zai’s Du, Innovent among winners

ASH 2020 snapshot: efficacy data in hot emerging areas

Innovation in a hurry: China biotechs see a fast track to global stage – survey

Products & Solutions

About Biocentury

Contact

Privacy & Legal